Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELOSEF '500' (cephradine) is an oral first-generation cephalosporin antibiotic in capsule form developed by Teva. It is indicated for bacterial infections susceptible to cephalosporins. Cephradine works by inhibiting bacterial cell wall synthesis, making it bactericidal against gram-positive and some gram-negative organisms.
Pre-Launch
Pre-launch status indicates emerging commercial opportunity; limited team size until market introduction and uptake are established.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VELOSEF '500' offers entry-level to mid-level positions in a pre-launch environment focused on market preparation and regulatory compliance. Career growth depends heavily on successful market introduction and differentiation strategy in a competitive generic-dominated antibiotic market.
Regulatory Affairs SpecialistBrand Manager
Worked on VELOSEF '500' at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.